KR20140121055A - Food composition with Agarum cribrosum against constipation - Google Patents
Food composition with Agarum cribrosum against constipation Download PDFInfo
- Publication number
- KR20140121055A KR20140121055A KR1020130037217A KR20130037217A KR20140121055A KR 20140121055 A KR20140121055 A KR 20140121055A KR 1020130037217 A KR1020130037217 A KR 1020130037217A KR 20130037217 A KR20130037217 A KR 20130037217A KR 20140121055 A KR20140121055 A KR 20140121055A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- constipation
- group
- food composition
- cholesterol
- Prior art date
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 235000013305 food Nutrition 0.000 title abstract description 24
- 241001512732 Agarum Species 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 9
- 241001474374 Blennius Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 17
- 235000005911 diet Nutrition 0.000 abstract description 10
- 230000037213 diet Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 39
- 235000012000 cholesterol Nutrition 0.000 description 17
- 235000013325 dietary fiber Nutrition 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 210000003608 fece Anatomy 0.000 description 12
- 238000009360 aquaculture Methods 0.000 description 11
- 244000144974 aquaculture Species 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003736 gastrointestinal content Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229960001571 loperamide Drugs 0.000 description 5
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001454694 Clupeiformes Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000019513 anchovy Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001685 Amylomaize Polymers 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000010369 Cascara Substances 0.000 description 1
- 244000025596 Cassia laevigata Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000006074 Colonic Diverticulosis Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010013559 Diverticulum intestinal Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000556215 Frangula purshiana Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 108010080123 HDL-triglyceride Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 241000269827 Sarda Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 description 1
- 229940068317 agarum clathratum extract Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940058505 cascara Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 description 1
- 229940050931 potassium citrate monohydrate Drugs 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- -1 yalapa Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 변비개선용 식품조성물에 관한 것으로, 더욱 상세하게는 구멍쇠미역을 함유하는 변비개선용 식품조성물에 관한 것이다.
The present invention relates to a food composition for improving constipation, and more particularly to a food composition for improving constipation containing an aquaculture starch.
경제의 급속한 발달로 우리의 생활은 예전에 비해 풍요로워졌지만 환경오염, 생활 스트레스, 운동량 부족, 식습관 변화로 인한 영양 불균형 등의 이유로 생활습관병을 포함한 각종 만성질환이 급속히 늘어나고 있다. 만성질환은 현재까지 의학적 방법이 주된 치료 방법으로 이용되어 왔지만, 치료의 한계성 및 치료약의 부작용 등으로 인해 많은 제약을 받고 있다. Due to the rapid development of the economy, our lives have become more prosperous than before, but chronic diseases such as lifestyle diseases are rapidly increasing due to environmental pollution, life stress, lack of exercise, and nutritional imbalance due to changes in eating habits. Although chronic medical treatment has been used as a main treatment method until now, it has been limited by the limitation of treatment and side effects of therapeutic drugs.
그런데, 식품 중에 함유된 유효성분에 의한 건강증진 및 질병예방 효과들이 여러 연구로부터 증명되면서, 식품이나 음식의 조절을 통해 생활습관으로 말미암은 만성질환의 예방이 점차 가능해지고 있다.However, as health promotion and disease prevention effects of active ingredients contained in foods are proved by various studies, prevention of chronic diseases due to lifestyle habits gradually becomes possible through control of food or food.
현대인은 생활 스트레스의 증가, 불규칙적이고 불균형된 식생활, 운동부족 등과 같은 복합적 생활요인들로 인해 장기능의 저하와 만성적 변비, 과민성 대장증후군, 설사, 장염 등 각종 대장 관련 질병을 겪고 있다. 변비가 발생하면, 체 내 유해 물질을 몸 밖으로 배설하는 작용이 제대로 이루어지지 않아 변의 독소가 장을 통해 혈액에 흡수됨으로써 여드름, 기미, 피부노화를 촉진시키기도 한다(Corfield AP, Carrol D, Myerscouh N, Probert CS. 2001. Mucins in the gastrointestinal tract in health and disease. Front Biosci 6: 1321-1327). 또한, 변비로 인해 장내 이상 발효로 생긴 유해물질 등이 두통, 식용부진, 복부 불쾌감, 알레르기의 원인이 되고, 나아가 치질, 대장게실증 및 대장암 발생과 뇌졸등 위험 등 2차 질환의 원인 될 가능성이 제시되고 있다(Park JG. 2005. Coloproctology. pp. 273-275. Ilchokak, Seoul, Korea).Modern people are suffering from various bowel related diseases such as diarrhea, chronic constipation, irritable bowel syndrome, diarrhea and enteritis due to complex life factors such as an increase in life stress, irregular and unbalanced dietary life, and lack of exercise. When constipation occurs, the toxic substances in the body are not excreted out of the body, and the toxins of the feces are absorbed into the blood through the intestines, thereby promoting acne, spots and skin aging (Corfield AP, Carrol D, Myerscouh N, Probert CS, 2001. Mucins in the gastrointestinal tract in health and disease, Front Biosci 6: 1321-1327). In addition, the harmful substances caused by abnormal fermentation caused by constipation in the intestines cause headache, poor food, malaise and allergies. Furthermore, the possibility of secondary diseases such as hemorrhoids, colonic diverticulosis, (Park JG, 2005. Coloproctology, pp. 273-275, Ilchokak, Seoul, Korea).
한편, 식이섬유는 인체의 소화효소에 의하여 분해되지 않는 난분해성의 복합 다당류로, 식이섬유가 풍부한 식품을 섭취하면 위에 포만감을 주어서 음식섭취량을 줄일 수 있으며, 배설물의 부피를 증가시키고 음식물의 장 통과 속도를 빠르게 하여 영양소의 흡수를 저하시키므로 비만 예방에도 도움이 된다. On the other hand, dietary fiber is a complex-type polysaccharide which is not decomposed by the digestive enzymes of the human body. When a food rich in dietary fiber is ingested, it is possible to reduce the food intake by giving a feeling of fullness to the dietary fiber, increase the volume of excrement, It speeds up and reduces the absorption of nutrients, which also helps prevent obesity.
식이섬유는 셀룰로오스(cellulose), 헤미셀룰로오스(hemicelluloses), 리그닌(lignin) 등 종류가 다양하다. 일반적으로 수용성 식이섬유(SDF,soluble dietary fiber)와 불용성 식이섬유(IDF, insoluble dietaryfiber)로 구분되는데, 구성 성분과 구조에 기인되는 물리화학적 성질에 따라 인체에 미치는 영향이 달라진다(Lee HJ, Hwang EH. 1997. Effects of alginic acid, cellulose and pectin level on bowel function in rats. Korean J Nutr 30: 456-477). Dietary fiber is diverse, including cellulose, hemicelluloses, and lignin. In general, it is divided into soluble dietary fiber (SDF) and insoluble dietary fiber (IDF). The effect on the human body depends on the physicochemical properties due to constitution and structure (Lee HJ, Hwang EH 1997. Effects of alginic acid, cellulose and pectin levels on bowel function in rats. J Nutr 30: 456-477).
수용성 식이섬유는 위에서 음식물 체류시간을 증가시켜 포만감을 제공하고 장내에서의 영양소 흡수속도를 느리게 하며, 지질대사에 관여하여 혈청 콜레스테롤을 조절하고, 동맥경화를 예방하며, 대장암의 발병률을 낮추는 것으로 보고되어 있다. Water soluble dietary fiber increases the residence time of food on the top to provide satiety, slows the rate of absorption of nutrients in the intestines, participates in lipid metabolism, regulates serum cholesterol, prevents arteriosclerosis, and lowers the incidence of colorectal cancer .
불용성 식이섬유는 수분 보유능이 커, 변을 묽게 하여 분변의 장내통과시간을 촉진하고, 분변 양을 증가시켜 변비를 예방하거나 치료하며, 대장 기능에 관련된 효과도 있는 것으로 알려져 있다.It is known that insoluble dietary fiber has a high water retention capacity and promotes the intestinal transit time of the feces by diluting the feces, preventing or treating constipation by increasing the amount of feces, and also having an effect on the colonic function.
한편, 구멍쇠미역(Agarum cribrosum)은 다시마과에 속하고 일본의 홋카이도, 쿠릴열도, 아메리카 태평양연안, 베링해에 분포하고, 우리나라에서는 동해안 중부 이북지방에 분포한다. 잎의 모양이 둥근 특징을 가지고 있고, 둥근 잎에는 많은 구멍이 있으며, 수심 30 m의 깊은 곳에 서식하며 최근에 식용으로 사용하게 되었다. 구멍쇠미역에 대한 연구로는 발암성 니트로사민 생성인자의 하나인 아질산염을 효과적으로 전화시켜 발암성 니트로사민 생성억제를 보고한 연구(Park YB. 2005. Determination of nitrite-scavenging activity of seaweed. J Korean Soc Food Sci Nutr 34:1293-1296), 만성병을 유발하는 5-리폭시제나아제(lipoxygenase)의 저해제가 구멍쇠미역 등의 수산생물에 많이 함유되어 있다는 연구(Cho SY, You BJ, Chang MH, Lee SJ, Sung NJ, Lee EH. 1994. Screening for porare lipoxygenase- inhibitor in unused marine resources by the polarographic method. Agricultural Chemistry and Biotechnology 37:451-455)도 보고되었으며, 최근에는 치매의 예방 및 치료를 위한 물질 탐색(Jeon YE, Yin XF, Lim SS, Chung CK, Kang IJ. 2012. Antioxidant activities and acetylcholinesterase inhibitory activities from seaweed extracts. J Korean Soc Food Sci Nutr 41:434-449), 영양성분 및 생리활성(Park SJ, Min KJ, Park TG. 2012. Nutritional Characteristics and Screening of the Biological Activity of Agarum cribrosum. Korean J Food & Nutr 25:842-849) 탐색 등의 연구가 활발히 이루어지고 있다.
On the other hand, Agarum cribrosum belongs to kelp, and it is distributed in Hokkaido, Kuril Islands, the Pacific coast of America, and the Bering Sea in Japan, and it is distributed in the northwestern part of the eastern coast in Korea. The leaves have rounded features, round leaves have many holes, they are deeply inhabited at 30m depth and have recently been used for edible purposes. A study of the hinge hole seaweed is a study by the phone, one of the nitrite of carcinogenic nitrosamines generated factor effectively reports the carcinogenic nitrosamine generation suppression (YB Park. 2005. Determination of nitrite-scavenging activity of seaweed. J Korean Soc Food Sci Nutr 34: 1293-1296 ) and a study on the inhibition of 5-lipoxygenase inducing chronic diseases in aquatic organisms such as aquaculture (Cho SY, You BJ, Chang MH, Lee SJ, Sung NJ, Lee EH. 1994. Screening for porare lipoxygenase- inhibitor in unused marine resources by the polarographic method. Agricultural Chemistry and Biotechnology 37: 451-455). Recently, the search for substances for prevention and treatment of dementia (Jeon YE, Yin XF, Lim SS, Chung CK, Kang IJ 2012. Antioxidant activities and acetylcholinesterase inhibitory activities from seaweed extracts. J Korean Soc Food Sci Nutr 41: 434-449), nutrients and physiological activity (Park SJ, Min KJ, Park TG 2012. Nutritional Characteristics and Screening of the Biological Activity of Agarum cribrosum . Korean J Food & Nutr 25: 842- 849) researches have been actively studied.
본 발명에서는 구멍쇠미역 투여가 동물의 체중변화와 식이효율 및 장내용물의 장통과시간과 배변상태에 미치는 영향을 확인하고, 변비예방용 식품조성물로 개발하여 제공하고자 한다.
In the present invention, the effect of the application of the aquaculture wastewater on body weight change, diet efficiency, intestinal transit time and bowel condition of the intestinal contents are examined and developed as a food composition for preventing constipation.
본 발명은 구멍쇠미역을 유효성분으로 포함하는 것을 특징으로 하는 변비개선용 식품조성물 제공한다. 하기 본 발명의 실험에 의할 경우, 구멍쇠미역에 현저한 변비개선능이 있음이 확인되었다. The present invention provides a food composition for improving constipation characterized by comprising an anchovy waxy marrow as an active ingredient. According to the experiment of the present invention as described below, it was confirmed that there was a remarkable ability to improve constipation in the seaweed.
한편, 본 발명의 변비개선용 식품 조성물은 구멍쇠미역을 포함하기만 하면 그 제형이 특별히 한정되지는 않으며, 일 예로 카페인 음료, 일반음료, 빵류, 과자류, 피자, 젤리, 면류, 아이스크림류, 알코올성 음료 및 그 밖의 선식, 건식 등 건강보조식품류 중 선택되는 어느 하나인 것일 수 있다. On the other hand, the composition for improving constipation according to the present invention is not particularly limited as long as it contains an aquaculture starch, and examples thereof include a caffeinated beverage, a general beverage, a bread, a confectionery, a pizza, a jelly, a noodle, Beverages, and other supplements, and health-supplement foods such as dry beverages.
한편, 본 발명의 변비개선용 식품조성물에 있어서, 구멍쇠미역은 바람직하게 분말 형태로 포함되는 것이 좋다. On the other hand, in the food composition for improving constipation of the present invention, the perilla starch is preferably contained in powder form.
한편, 본 발명의 변비개선용 식품조성물에 있어서, 구멍쇠미역은 바람직하게 5~10중량% 포함되는 것이 좋다.
On the other hand, in the food composition for improving constipation of the present invention, the starchy seaweed is preferably contained in an amount of 5 to 10% by weight.
본 발명에서는 구멍쇠미역에 우수한 변비 개선능이 있음을 확인할 수 있었다. 따라서, 본 발명의 구멍쇠미역은 변비개선능을 갖는 식품조성물로 개발되어 활용될 수 있다.
In the present invention, it was confirmed that there is a good ability to improve constipation in the aquaculture seaweed. Therefore, the starchy seaweed of the present invention can be developed and utilized as a food composition having constipation-improving ability.
도 1은 변비 유도쥐 분변의 수분함량에 대해 구멍쇠미역이 미치는 영향을 보여준다. 그래프 중 a~d는 유의적(p<0.05)으로 다름을 의미한다. N: 정상식이군, C: 정상식이 및 로퍼아마이드 처리군(변비유도군), SD5: 5% 구멍쇠미역 및 로퍼아마이드 처리군, SD10: 10% 구멍쇠미역 및 로퍼아마이드 처리군.Figure 1 shows the effect of the aquaculture seaweed on the water content of constipation-induced rat feces. In the graph, a ~ d means significant (p <0.05). N: Normal diet, C: Normal diet and roperamide treatment group (constipation inducing group), SD5: 5% aortic anchovy and ropamide treatment group, SD10: 10%
이하, 본 발명의 내용을 하기 실험 및 실시예를 통해 더욱 자세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 그와 등가의 기술적 사상의 변형까지를 포함한다.
Hereinafter, the present invention will be described in more detail with reference to the following experiments and examples. However, the scope of the present invention is not limited to the following embodiments, and includes modifications of equivalent technical ideas.
[실시예 1: 구멍쇠 미역 급여에 의한 생리학적 변화 관찰][Example 1: Observation of physiological changes by the treatment of the horseradish seaweed]
본 실험에 사용된 구멍쇠 미역(Agarum cribrosum)은 2011년도에 강원도 동해안에서 채취한 것을 경포대영어조합법인에서 공여받았다. 깨끗하게 수세한 생체를 냉풍제습건조기(TJHP-1003, Joogang Precision, Daegu, Korea)에서 건조하여 사용하였다.The Agarum cribrosum used in this experiment was obtained from Kyungpook University English Language Institute in 2011, which was collected from the east coast of Gangwon Province. The washed body was washed with a cold air dehumidifying dryer (TJHP-1003, Joogang Precision, Daegu, Korea) and used.
실험동물은 4주령 Sprague-Dawley종 수컷 흰쥐(Central Lab animal, Seoul, Korea)를 환경이 조절된 사육실(기온 20℃, 습도 55%, 12시간 dark/light cycle)에서 펠렛형 고형사료(Jeil animal feed Co., Daejeon, Korea)로 2주간 사육하여 평균 체중이 200 g정도로 성장한 6주령의 쥐를 사용하여 평균 체중이 유사하도록 10마리씩 4군으로 나누었다. The animals were housed in 4-week-old Sprague-Dawley male rats (Central Lab animal, Seoul, Korea) in a controlled environment (temperature 20 ℃, humidity 55%, dark / feed Co., Daejeon, Korea) and were divided into four groups of 10 rats, each weighing 200 g.
정상대조군을 제외한 세 군의 동물은 전 실험기간 동안 실험식이에 로퍼아마이드(loperamide, Sigma, St. Louis, MO, USA)를 0.03% 수준으로 첨가 투여하여 변비상태를 유발하였다. 정상군(N)과 대조군(C)은 AIN-76 사료를 공급하였고, SD5군과 SD10군은 구멍쇠미역분말 5% 및 10%를 첨가한 사료를 5주 동안 자유 급이하였다. 모든 실험 식이는 총 탄수화물(65%), 총 단백질(20%), 총지방(15%)의 비율을 동일하게 하여, 이소칼로리 식이(isocaloric diet)가 되도록 제조하였으며, 실험 식이의 조성은 표 1과 같았다. The animals were fed loperamide (Sigma, St. Louis, Mo., USA) at a level of 0.03% during the entire experimental period, except for the normal control group. The control group (C) and the control group (C) were fed AIN-76 and SD5 and SD10 groups, respectively. All experimental diets were made to be isocaloric diets with the same percentages of total carbohydrate (65%), total protein (20%) and total fat (15%). Respectively.
powder Agarum cribrosum
powder
2)AIN-76 vitamin mix (g/kg mix): thiamin-HCl 0.6, riboflavin 0.6, pyridoxine HCl 0.7, nicotinic acid 3, D-calcium pantothenate 1.6, folic acid 0.2, cyanocobalamin 0.001, retinyl palmitate 0.8 (500,000 IU/g), DL-a-tocopheryl acetate 20 (2,501 IU/g), cholecalciferol 0.0025, menaquinone 0.005, sucrose to make 1kg
3)AIN-76 mineral mix (g/kg mix): calcium phosphate dibasic 500, sodium chloride 74, potassium citrate monohydrate 220, potassium sulfate 52, magnesium oxide 24, manganous carbohydrate 3.5, ferric citrate 6, zinc carbonate 1.6, cupric carbonate 0.3, potassium iodate 0.01, sodium selenite 0.01, chromium potassium sulfate 0.55, sucrose to make 1 kg 1) N: normal diet group, C: normal diet and loperamide-treated group, SD5: 5% of agarum cribrosum powder and loperamidetreated group, SD10: 10% of agarum cribrosum powder and loperamide-treated group.
2) AIN-76 vitamin mix (g / kg mix): thiamin-HCl 0.6, riboflavin 0.6, pyridoxine HCl 0.7, nicotinic acid 3, D-calcium pantothenate 1.6, folic acid 0.2, cyanocobalamin 0.001, retinyl palmitate 0.8 g), DL-a-tocopheryl acetate 20 (2,501 IU / g), cholecalciferol 0.0025, menaquinone 0.005, sucrose to make 1 kg
3) AIN-76 mineral mix (g / kg mix): calcium phosphate dibasic 500, sodium chloride 74, potassium citrate monohydrate 220, potassium sulfate 52, magnesium oxide 24, manganous carbohydrate 3.5, ferric citrate 6, 0.3, potassium iodate 0.01, sodium selenite 0.01, chromium potassium sulfate 0.55, sucrose to make 1 kg
실험 결과는 SPSS package program(version 12.0)을 이용하여 평균±표준오차로 나타내었으며, 각 군의 평균치간의 차이에 대한 유의성은 one-way ANOVA (analysis of variance)와 Duncanmultiple comparison test에 의해 p<0.05 수준에서 검증하였다.
The test results were expressed as mean ± standard error using the SPSS package program (version 12.0). The significance of the difference between the mean values of each group was analyzed by one-way ANOVA (Duncan Multi- Respectively.
(1) 체중변화와 식이효율 측정 (1) Measurement of body weight change and diet efficiency
실험기간 동안 식이섭취량은 일주일에 3회, 체중은 일주일에 1회 일정한 시간에 측정하였고, 식이효율(feed efficiency ratio:FER)은 사육기간 동안의 체중증가량을 같은 기간 동안 섭취한 식이량으로 나누어 산출하였다. During the experimental period, the dietary intake was measured three times a week, the body weight was measured once a week, and the feed efficiency ratio (FER) was calculated by dividing the body weight gain during the rearing period by the dietary intake during the same period Respectively.
실험기간 5주 동안 정상대조군은 평균 150 g의 체중 증가를 보인데 비해, 변비유발군들은 평균 19~64 g의 유의적으로 낮은 체중증가를 보였다(표 2). During the 5-week study period, the normal control group had an average weight gain of 150 g, whereas the constipation-inducing group had a significantly lower weight gain of 19 to 64 g (Table 2).
2)FER: feed efficiency ratio (weight gain g/feed intake g)
3)Mean(n=10)
4)ns: not significant
5)Values with different superscript within a column are significantly different at =0.05 by Duncanmultiple range test 1) See the footnote of Table 1
2) FER: feed efficiency ratio (weight gain g / feed intake g)
3) Mean (n = 10)
4) ns: not significant
5) Values with different superscript within a column are significantly different at = 0.05 by Duncanmultiple range test
로퍼아마이드는 배변 기간의 증가, 대장 연동 운동의 저하와 더불어 일정기간 연속적으로 투여하면 대장 관내 점액질의 두께가 얇아져서 대장 내용물의 이동에 지장을 초래하여 변비를 유발하고, 그 증상이 사람에게서 일어나는 변비와 유사하다고 보고되어 있다(Cepinskas G. 1993. Adaptive cytoprotection in the small intestine: Role of mucus. Am J Physiol 264:921-927). In addition to increasing bowel movements and decreased bowel movements, the administration of looperamide decreases the thickness of the intestinal mucus when administered continuously for a certain period of time, causing constipation and causing constipation, (Cepinskas G. 1993. Adaptive cytoprotection in the small intestine: Role of mucus. Am J Physiol 264: 921-927).
쉬모토요돔 등(Shimotoyodome A, Meguro S, Hase T, Tokimitsu I, Sakata T. 2000. Decreased colonic mucus in rats with loperamide-induced constipation. Comp Biochem Physiol 126:203-211)은 로퍼아마이드를 투여할 경우 복부팽만, 식욕 저하 등의 증상에 의해 실험동물의 식이섭취량이 감소하는 경향을 보였다고 보고한 바 있으며, 본 실험에서 변비유발군들의 평균 체중 증가가 정상대조군에 비해 낮은 이유도 식이섭취량의 감소에 따른 체중증가의 억제의 결과로 보여진다. 식이효율은 N군에 비해 C군, SD 5군, SD 10군에서 유의적으로 낮게 나타났다. Shimotoyodome A, Meguro S, Hase T, Tokimitsu I and Sakata T. 2000. Decreased colonic mucus in rats with loperamide-induced constipation. Comp Biochem Physiol 126: 203-211) The results showed that the dietary intake of the experimental animals tended to decrease due to symptoms such as bloating and appetite. In this experiment, the weight gain of the constipation-inducing group was lower than that of the normal control group, As shown in Fig. Dietary efficiency was significantly lower in Group C, SD 5, and SD 10 than in Group N.
(2) 장 통과시간((2) The passage time ( gastrointestinalgastrointestinal ( ( GIGI ) ) transittransit timetime ) 측정) Measure
장 내용물의 장 통과시간(GI transit time)을 측정하고자 하였다. (GI transit time) of intestinal contents.
실험식이 투여 후 4주째에 실험동물을 12시간 절식시킨 후, 장 통과 표지물질로 카르민 레드(carmine red, Sigma)를 0.5% 혼합한 식이 10 g씩을 먼저 급여하여 다 섭취시킨 후 실험 식이를 평상일과 같은 시간에 제공하였다. 카르민 레드(carmine red) 혼합식 급여 후 30분 간격으로 변 중에 적색 표지가 나타나는지를 확인하여 표지 혼합식 급여 시간으로부터 표지가 변 중에 처음 나타난 시간까지의 간격을 장 통과시간으로 하였다.At 4 weeks after the experiment, the experimental animals were fasted for 12 hours, and 10 g of carmine red (Sigma) 0.5% And at the same time as work. Carmine red (mixed carmine red) was fed at intervals of 30 minutes. The interval from the label mixed feeding time to the first appearance time of the label was defined as the passage time.
실험결과는 표 3과 같았다. The experimental results are shown in Table 3.
2)NS: not signficant. 1) See the footnote of Table 1
2) NS: not signficant.
실험식이 섭취후 4주째 측정한 장통과시간을 보면 대조군이 853.1분이었고, SD 10군에서 유의적이지는 않으나 789.7분으로 감소하였다. At the 4th week after the ingestion, the control period was 853.1 minutes, but the decrease was not significant in the SD 10 group, but decreased to 789.7 minutes.
스필러 등(Spiller GA, Chernoff MC, Hill RA, Gates JE, Nassar JJ, Shipley EA. 1980. Effect of purified cellulose, pectin, and a low residue diet on fecal volatile fatty acids, transit time and fecal weight in humans. Am J Clin Nutr 33: 754-759)은 사람에게 셀룰로오스와 펙틴을 섭취시켰을 때 셀룰로오스는 유의적으로 장 통과시간을 감소시켰으나, 펙틴은 대조군에 비해 오히려 다소 증가하는 경향을 보여주었다고 보고하였다. 즉, 불용성 식이섬유는 총 장 통과시간을 유의적으로 감소시키나 수용성 식이섬유는 그러한 효과가 적은 것으로 보고되어 있다(Kim MH. 2000. The water-soluble extract of chicory reduces cholesterol uptake in gut-perfused rats. Nutr Res 20:1017-1026). Spiller GA, Chernoff MC, Hill RA, Gates JE, Nassar JJ, Shipley EA 1980. Effect of purified cellulose, pectin, and a low residue diet on fecal volatile fatty acids, transit time and fecal weight in humans. Am J Clin Nutr 33: 754-759) reported that when cellulose and pectin were administered to humans, cellulose significantly decreased intestinal transit time, but pectin tended to increase rather than the control. In other words, insoluble dietary fiber significantly reduces the total intestinal transit time, but soluble dietary fiber has been reported to have such a low effect (Kim MH, 2000. The water-soluble extract of chicory reduces cholesterol uptake in gut-perfused rats. Nutr Res 20: 1017-1026).
일반적으로 불용성 식이섬유는 대장에서 박테리아에 의한 분해에 저항성을 가지고 있어 물리적 구조를 유지하기 때문에 위에서 물을 흡수, 팽윤하여 콜로이드상이 되어 배설물의 용적 및 무게를 증가시킴으로 배변량 및 배변 횟수를 증가시킨다(Blackburn NA, Johnson IT. 1981. The effect of guar gum on the viscosity of the gastrointestinal contents and glucose uptake form the perfused jejunum in the rat. Brit J Nutr 46:239-246). 또한, 장내 미생물군의 생존을 유지해 잔사의 보수력을 증가시킬 뿐만 아니라 직접적으로 부피를 증가시켜 장벽을 자극하고 장운동을 촉진시킴으로써 변의 대장 통과시간을 단축시킬 수 있다고 알려져 있다(Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN. 1996. Digestion and physiological properties of resistant starch in the human large bowel. Brit J Nutr 75:733-747). In general, insoluble dietary fiber is resistant to degradation by bacteria in the large intestine, so it maintains its physical structure, so it absorbs and swells water from above to become a colloidal phase, which increases the volume and weight of excretion, thereby increasing the number of bowel movements and bowel movements NA, Johnson IT 1981. The effect of guar gum on the viscosity of the gastrointestinal contents and the glucose uptake form of the perfused jejunum in the rat Brit J Nutr 46: 239-246). In addition, it is known that it maintains the viability of intestinal microorganisms and increases the water holding capacity of the residue as well as it can directly shorten the colon transit time by stimulating the barrier and promoting the intestinal tract by directly increasing the volume (Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN 1996. Digestion and physiological properties of resistant starch in the human large bowel. Brit J Nutr 75: 733-747).
구멍쇠미역은 본 발명에서 장통과시간의 단축효과가 나타나 변비증세의 완화에 도움이 될 것으로 판단되었다.
In the present invention, it was judged that the oral seaweed was effective in reducing constipation symptoms by shortening the transit time.
(3) 조직 중량 및 장 길이 측정 (3) Tissue weight and length measurement
변비를 유발시키면서 식이섬유를 급이한 흰쥐의 조직 중량 및 장 길이를 측정하고자 하였다.The purpose of this study was to evaluate the tissue weight and length of diabetic rats fed constipation.
사육기간이 끝난 실험동물들을 12시간 절식시킨 후 희생일 아침 1% 케타민 하이드로클로라이드(ketamine hydrochloride, Sigma) 용액을 체중 100 g 당 0.2 mL 양으로 복강 내 주사하여 마취시킨 후 개복하였다. 간, 신장은 적출 후 지방을 제거하고 냉장 생리 식염수로 3회 세척 후 거즈로 수분을 제거하여 중량을 측정하였고, 소장과 대장은 채취한 후 바로 길이를 측정하였다.After the breeding period, the animals were fasted for 12 hours, and 1% ketamine hydrochloride (Sigma) solution was inoculated intraperitoneally with 0.2 mL per 100 g of body weight on the day of sacrifice. Liver and kidney were removed after removing fat, washed three times with chilled physiological saline, and water was removed by gauze to measure the weight. The length of the small intestine and colon was measured immediately after collection.
변비를 유발시키면서 식이섬유를 급이한 흰쥐의 간 및 신장의 무게변화는 표 4와 같이, 체중 대비 간의 무게는 모든 실험군에서 정상군과 차이가 없었으며, 신장의 무게도 각 실험군에서 차이가 나타나지 않았다.As shown in Table 4, the weight of liver and kidneys in rats fed dietary fiber with constipation was not different from that of normal rats in all experimental groups, and the weight of kidneys was different in each experimental group I did.
2)Mean(n=10)
3)ns: not significant 1) See the footnote of Table 1
2) Mean (n = 10)
3) ns: not significant
가르시아 등(Garcia DF, Garcia MV, Bayon JE, Gonzalez GJ. 1996. Pectin feeding influences fecal bile acids excretion, hepatic bile acid, and cholesterol synthesis and serum cholesterol in rats. J Nutr 126:1766-1771)의 연구에서도 정상상태에서 식이섬유 종류별 섭취에 따른 간과 신장 무게는 유의적인 차이가 없다고 보고하고 있어 본 실험의 결과와 일치했다. Garcia DF, Garcia MV, Bayon JE, Gonzalez GJ 1996. Pectin feeding influenza fecal bile acids excretion, hepatic bile acid and cholesterol synthesis and serum cholesterol in rats. J Nutr 126: 1766-1771) And liver and kidney weights were not significantly different between dietary fiber types.
실험동물들의 소장 및 대장의 길이는 변비의 유무와 식이섬유 급원에 따른 군간 유의적인 차이가 없었다(상기 표 4). 설 등(Seol SM, Bang MH, Choi OS, Kim WK. 2003. Effects of high amylose starch on lipid metabolism and immune response in rats. J Korean Soc Food Sci Nutr 32:450-457)도 식이를 4주간 흰쥐에게 사육한 결과 소장의 길이는 식이에 의해 영향을 받지 않았다고 보고하여 식이섬유의 종류와 양에 의한 소장의 변화가 관찰되지 않은 본 연구 결과와 일치하였다. 이는 식이섬유로 인한 영양소 흡수저해에 적응하기 위해 초기에는 소장의 길이가 증가하기도 하지만 섬유소가 장 내용물의 체류시간을 지연시켜 장관 벽과 영양소 간의 접촉시간을 늘려주게 됨에 따라 적응의 필요성이 줄어들면서 다시 정상 길이로 회복되기 때문인 것으로 설명되고 있다.
The intestinal and colon lengths of the experimental animals were not significantly different between the groups depending on the presence or absence of constipation and dietary fiber source (Table 4). ( Soc Food Sci Nutr 32: 450-457) was used to evaluate the effects of high-amylose starch on lipid metabolism and immune response in rats for 4 weeks in rats As a result of breeding, the length of the small intestine was reported to be unaffected by the diet and was consistent with the results of this study in which no changes in the small intestine due to the type and amount of dietary fiber were observed. This is because the length of the small intestine initially increases to accommodate the inhibition of nutrient absorption by the dietary fiber, but since the fiber retards the residence time of the intestinal contents and increases the contact time between the intestinal wall and the nutrient, the need for adaptation is reduced And restored to normal length.
(4) 분변량 및 수분함유 측정(4) Measurement of fecal content and moisture content
구멍쇠 미역 첨가 식이가 변비 증세 호전에 어떠한 영향을 미치는지를 관찰하고자 하였다.And to investigate the effect of dietary supplementation on the improvement of constipation symptoms.
실험동물을 희생하기 전 24시간 동안 배설되는 분변을 하루에 2회 수집하여 즉시 분변 무게를 측정하였다. 수집된 분변은 105℃에서 항량에 달할 때까지 건조시킨 후에 건조 중량을 측정하고, 건조 전후 중량의 차이를 분변의 수분함량으로 하였다. The feces excreted for 24 hours before the sacrifice of the experimental animals were collected twice a day and the feces weight was measured immediately. The collected feces were dried until reaching a constant weight at 105 ° C., and the dry weight was measured. The difference in weight before and after drying was regarded as the moisture content of the feces.
분변량을 측정한 결과는 표 5와 같았다.The results of measurement of fecal incidence were as shown in Table 5.
2)Mean(n=10)
3)Values with different superscript within a column are significantly different at =0.05 by Duncanmultiple range test 1) See the footnote of Table 1
2) Mean (n = 10)
3) Values with different superscript within a column are significantly different at = 0.05 by Duncanmultiple range test
N군의 1일 평균 분변량은 2.84 g, C군은 1.34 g, SD 5군은 1.57 g, SD 10군은 2.02 g으로 나타났는데, 구멍쇠 미역의 섭취가 변비 증상 호전에 영향을 줌을 확인할 수 있었다. The mean daily fecundity of the N group was 2.84 g, the C group was 1.34 g, the SD 5 group was 1.57 g, and the SD 10 group was 2.02 g. The intake of the aquaculture starch affects constipation symptoms there was.
분변의 수분함량 측정 결과, 로퍼아마이드를 단독 투여한 대조군(C) 분변의 수분함량이 정상군(N)에 비해 유의적으로 감소하여 로포아마이드 투여로 인해 변비가 유발된 것을 확인하였으며, 구멍쇠미역 5% 및 10%가 함유된 사료를 급이한 군(SD5, D10)은 정상군에 비해 분변의 수분함량이 각각 1.6배 및 2.1배 증가하였다(도 1). 이와 같은 결과는 구멍쇠미역의 변비 개선 가능성을 시사하는 것이다.
As a result of measuring the moisture content of feces, it was confirmed that the water content of the feces of the control group (C) administered alone with ropuramide was significantly lower than that of the normal group (N), and the constipation was induced by the administration of ropamide, (SD5, D10) fed with feed containing 5% and 10% increased the moisture content of the feces by 1.6 and 2.1 times, respectively, compared to the normal group (Fig. 1). These results suggest the possibility of improvement of constipation in aquaculture.
(5) 혈중 콜레스테롤 및 중성지방 농도 측정 (5) Measurement of blood cholesterol and triglyceride levels
구멍쇠 미역을 급이한 흰쥐의 혈청 중 콜레스테롤 및 중성지방(triglyceride) 함량 변화를 측정하고자 하였다. 혈청분석은 시험종료일에 실험동물을 마취시킨 후 개복하여 후대정맥에서 채혈하였으며, 혈액을 원심분리 하여 혈청을 분리 후, 분석용 키트(Asan Pharmaceutical Co.,Seoul, Korea)를 이용하여 총콜레스테롤, HDL-콜레스테롤, 중성지방(triglyceride)을 측정하였다.(표 6).The purpose of this study was to evaluate the changes of cholesterol and triglyceride contents in serum of rats fed with aquaculture. Serum was collected by centrifugation of the blood, and analyzed with a kit (Asan Pharmaceutical Co., Seoul, Korea) for total cholesterol, HDL - Cholesterol and triglyceride were measured (Table 6).
2)Mean(n=10)
3)Values with different superscript within a column are significantly different at =0.05 by Duncanmultiple range test 1) See the footnote of Table 1
2) Mean (n = 10)
3) Values with different superscript within a column are significantly different at = 0.05 by Duncanmultiple range test
측정 결과, 혈청 중 총 콜레스테롤 함량은 구멍쇠 미역 5% 급이군(SD5)에서 로퍼아마이드로 변비를 유발한 대조군(C)에 비해 3.5% 감소하였으나, 유의적인 차이는 없었으며, 구멍쇠 미역 10% 급이군(SD10)은 40.21 mg/dL로 33.5% 감소하여 구멍쇠 미역의 섭취량이 높아질수록 흰쥐의 혈중 콜레스테롤 함량이 감소하였다. The total cholesterol content in the serum was decreased by 3.5% compared to the control group (C) which caused constipation in the 5% group (SD5), but there was no significant difference. The SD10 decreased by 33.5% at 40.21 mg / dL, and the blood cholesterol content of the rats decreased as the intake of the aquacultured seaweed increased.
HDL-콜레스테롤은 대조군에 비해 SD5군과 SD10군이 각각 22.9% 및 27.7% 감소하였으나 첨가 수준에 따른 유의적인 차이는 확인할 수 없었으며, 혈중 중성지방 농도는 대조군(C)에 비해 SD10군에서 22.8% 감소한 것으로 나타났다.
HDL-cholesterol was decreased in SD5 and SD10 groups by 22.9% and 27.7%, respectively, but the difference of HDL-cholesterol was not significantly different according to the addition level. Serum triglyceride concentration in the SD10 group was 22.8% Respectively.
(6) 혈중 GOT, GPT, BUN 및 포도당 농도 측정 (6) Measurement of blood GOT, GPT, BUN and glucose concentration
구멍쇠미역을 급이한 흰쥐의 혈청 중 GOT, GPT, BUN 및 포도당 함량 변화를 측정하고자 하였다. STANBIO사(Boerne, TX,USA)의 측정용 kit를 이용하여 GOT, GPT, BUN 및 포도당을 분석하였다(표 7)The changes of GOT, GPT, BUN and glucose content in serum of rats fed with aorticoid seaweed were measured. GOT, GPT, BUN and glucose were analyzed using a measurement kit of STANBIO (Boerne, TX, USA) (Table 7)
2)Mean(n=10)
3)3)Values with different superscript within a column are significantly different at =0.05 by Duncanmultiple range test 1) See the footnote of Table 1
2) Mean (n = 10)
3) 3) Values with different superscripts within a column are significantly different at = 0.05 by Duncanmultiple range test
간기능의 지표로 간 기능에 이상이 있을 때 수치가 증가하는 것으로 알려져 있는 GOT(glutamic oxaloacetic transaminase) 및 GTP (glutamic pyruvic transaminase)는 각 실험군에서 차이가 나타나지 않았다. 하지만, 신 장 기능 장애의 임상지표인 BUN(blood urea nitrogen) 농도는 대조군(C)에 비해 SD10 군에서 낮게 나타났다. 혈중 포도당 농도는 각 실험군 간에 유의적인 차이가 없었다.
Glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GTP), which are known to increase in liver function when liver function is abnormal, showed no difference in each experimental group. However, BUN (blood urea nitrogen), a clinical indicator of renal dysfunction, was lower in the SD10 group than in the control group (C). There was no significant difference in blood glucose concentration among the experimental groups.
(7) 간 조직 중 콜레스테롤 및 중성 지방 함량 측정 (7) Determination of cholesterol and triglyceride content in liver tissue
간 조직 내 콜레스테롤 및 중성 지방 함량을 측정하고자 하였다.Cholesterol and triglyceride contents in liver tissue.
간 조직 1 g에 클로로포름-메탄올(2:1, v/v) 용액 6 mL을 첨가하여 냉장상태에서 3일간 방치하며 수시로 교반한 후, 2 mL의 증류수를 첨가하여 1,900×g에서 20분간 원심분리시킨 다음 지질이 녹아있는 클로로포름 층을 피펫으로 취하였다. 6 mL of chloroform-methanol (2: 1, v / v) solution was added to 1 g of liver tissue, left to stand for 3 days in a refrigerated state and stirred for a few hours. 2 mL of distilled water was added and centrifuged at 1,900 × g for 20 minutes And then the chloroform layer in which the lipid was dissolved was pipetted.
간 조직 내의 총콜레스테롤 분석 결과는 표 8과 같았다. The results of total cholesterol analysis in liver tissues were as shown in Table 8.
2)Mean(n=10)
3)Values with different superscript within a column are significantly different at =0.05 by Duncanmultiple range test 1) See the footnote of Table 1
2) Mean (n = 10)
3) Values with different superscript within a column are significantly different at = 0.05 by Duncanmultiple range test
구멍쇠 미역 급이군(SD5, SD10) 모두 정상군(N) 및 대조군(C)에 비해 총콜레스테롤 함량이 감소하였으며, 로퍼아마이드 투여에 의해 감소되었던 HDL-콜레스테롤은 구멍쇠 미역 급이시 대조군(C)에 비해 증가하였으나 유의적인 차이는 없었다. 또한, 중성지방 함량은 총콜레스테롤과 마찬가지로 구멍쇠 미역 급이군(SD5, SD10)이 정상군(N)과 대조군(C)에 비해 감소하였다. 이와 같은 사실로부터, 구멍쇠 미역이 간에 중성지방 축적을 방지하는 효과가 있는 것으로 판단되나 구멍쇠 미역 첨가량에 따른 콜레스테롤 및 중성지방 차이는 나타나지 않아 추후 첨가량에 대한 추가적인 연구가 이루어져야 할 것으로 사료된다.
The total cholesterol content was decreased compared to the normal group (N) and the control group (C), and the HDL-cholesterol decreased by the looperamide treatment was higher in the control group (C ), But there was no significant difference. In addition, triglyceride content was decreased compared to normal group (N) and control group (C), as well as total cholesterol (SD5, SD10). From this fact, it is considered that the aquaculture starch has an effect of preventing the accumulation of triglyceride in the liver, but the cholesterol and triglyceride difference according to the addition amount of the aquaculture starch does not appear, so further study on the addition amount should be made.
[[ 실시예Example 2: 변비개선용 식품 조성물 제조] 2: Preparation of food composition for improving constipation]
실시예 2에서는 하기와 같이 변비개선용 식품 조성물을 제조하였다.In Example 2, a food composition for improving constipation was prepared as follows.
(1) 선식 제조 (1) Manufacturing of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 준비하였다. 검정콩, 검정깨 및 들깨 각각을 공지의 방법으로 쪄서 건조시킨 후 배전 및 분쇄하여 입도 60메쉬의 분말로 준비하였다. 이후, 현미 30중량%, 율무 15중량%, 보리 20중량%, 찹쌀 9중량%, 들깨 7중량%, 검정콩 8중량%, 검정깨 3중량%, 구멍쇠미역 7중량%, 영지 0.5중량% 및 지황 0.5중량%을 혼합하여 선식을 제조하였다.
Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and then the mixture was prepared into powder having a particle size of 60 mesh by a pulverizer. Black beans, black sesame seeds and perilla seeds were each steamed and dried by known methods, and then power distribution and pulverization were carried out to prepare powder having a particle size of 60 mesh. Thereafter, 30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley, 9% by weight of glutinous rice, 7% by weight of perilla seeds, 8% by weight of black soybeans, 3% by weight of black sesame seeds, 7% And 0.5 wt% of sulfuric acid were mixed to prepare an electric wire.
(2) 비스킷 제조 (2) Manufacturing of biscuits
박력 1급 22.59중량%, 중력 1급 19.22중량%, 정백당 4.80중량%, 식염 0.73중량%, 포도당 0.78중량%, 팜쇼트닝 11.78중량%, 암모니움 1.54중량%, 중조 0.17중량%, 중아황산나트륨 0.16중량%, 쌀가루 1.45중량%, 비타민 B₁0.0001중량%, 비타민 B₂0.0001중량%, 밀크향 0.04중량%, 물 20.6998중량%, 전지분유 1.16중량%, 대용분유 0.29중량%, 제일인산칼슘 0.03중량%, 살포염 0.29중량% 및 분무유 7.27중량%와 구멍쇠미역 7중량%를 배합하여 통상의 방법으로 비스킷을 제조하였다.
, The grapefruit first grade 22.59 wt.%, The gravity first grade 19.22 wt.%, The whiteness 4.80 wt.%, The salt 0.73 wt.%, The glucose 0.78 wt.%, The palm shortening 11.78 wt.%, The ammonia 1.54 wt.%, The bicarbonate 0.17 wt. 1.45 weight% of rice flour, 0.0001 weight% of vitamin B1, 0.0001 weight% of vitamin B2, 0.04 weight% of milk fractions, 20.6998 weight% of water, 1.16 weight% of whole milk powder, 0.29 weight% 0.29% by weight of spray salt, and 7.27% by weight of spray oil and 7% by weight of an anhydrous starch, respectively, to prepare a biscuit by a conventional method.
(3) 건강음료 제조 (3) Health drinks manufacturing
꿀 0.26중량%, 치옥토산아미드 0.0002중량%, 니코틴산아미드 0.0004중량%, 염산리보플라빈나트륨 0.0001중량%, 염산피리독신 0.0001중량%, 이노시톨 0.001중량%, 오르트산 0.002중량%, 물 92.7362중량% 및 구멍쇠미역 7중량%를 배합하여 통상의 방법으로 건강 음료를 제조하였다.0.0001% by weight of honey, 0.0002% by weight of chitosanic acid amide, 0.0004% by weight of nicotinic acid amide, 0.0001% by weight of sodium riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 0.001% by weight of inositol, 0.002% by weight of orthoacids, And 7% by weight of seaweed were mixed to prepare a health drink.
Claims (3)
The composition for improving constipation according to any one of claims 1 to 3,
구멍쇠미역은,
분말 형태로 포함되는 것을 특징으로 하는 변비개선용 식품조성물.
The method according to claim 1,
Hole seaweed,
Wherein the composition is contained in powder form.
구멍쇠미역은,
5~10중량% 포함되는 것을 특징으로 하는 것을 변비개선용 식품조성물. 3. The method of claim 2,
Hole seaweed,
5 to 10% by weight of the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130037217A KR101459665B1 (en) | 2013-04-05 | 2013-04-05 | Food composition with Agarum cribrosum against constipation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130037217A KR101459665B1 (en) | 2013-04-05 | 2013-04-05 | Food composition with Agarum cribrosum against constipation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140121055A true KR20140121055A (en) | 2014-10-15 |
KR101459665B1 KR101459665B1 (en) | 2014-11-12 |
Family
ID=51992704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130037217A KR101459665B1 (en) | 2013-04-05 | 2013-04-05 | Food composition with Agarum cribrosum against constipation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101459665B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102154905B1 (en) | 2018-11-27 | 2020-09-10 | 동아대학교 산학협력단 | The fermented plum liquid for preventing inflammatory bowel disease and improving constipation and method for manufacturing the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101125185B1 (en) * | 2009-10-09 | 2012-03-19 | 한국식품연구원 | a-amlyase inhibitor containing the extracts from oceanic life species for anti-obesity |
-
2013
- 2013-04-05 KR KR1020130037217A patent/KR101459665B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101459665B1 (en) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Franco et al. | Psyllium (Plantago ovata Forsk): From evidence of health benefits to its food application | |
CN101606704B (en) | Dietary fiber food with various functional actions | |
Choi et al. | Volatile N-nitrosamine inhibition after intake Korean green tea and Maesil (Prunus mume SIEB. et ZACC.) extracts with an amine-rich diet in subjects ingesting nitrate | |
JP6526021B2 (en) | Composition comprising okra for use in the reduction of dietary fat absorption | |
CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
CN102429183B (en) | Fruit-vegetable composition with functions of enhancing immunity and relaxing bowels and preparation method thereof | |
Son et al. | Effect of adlay, buckwheat and barley on lipid metabolism and aorta histopathology in rats fed an obesogenic diet | |
Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
Fotschki et al. | Effects of dietary addition of a low-pectin apple fibre preparation on rats | |
Azene et al. | Nutritional, health benefits and toxicity of underutilized garden cress seeds and its functional food products: a review | |
US20170007630A1 (en) | Composition and method of delivery of l-arabinose and select compounds | |
KR101459665B1 (en) | Food composition with Agarum cribrosum against constipation | |
KR101487769B1 (en) | Food Composition for Bowel Movement Promotion and Diet using Aspergillus oryzae | |
CN115968977A (en) | Pet food for losing weight and preparation method thereof | |
Preuss et al. | Chitosan as a dietary supplement for weight loss: a review | |
CN104432068A (en) | Weight-losing health food | |
KR101373493B1 (en) | Composition comprising Hizikia fusiformis for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
KR101219779B1 (en) | Sweet jelly food composition and its manufacturing method which is effective for reducing body weight and body fats | |
Matsuzaki et al. | Application of seaweeds to human nutrition and medicine | |
JP2011152105A (en) | Food product for promoting alkylphenol-based compound excretion | |
JP2007215517A (en) | Processed food of rush, and method for ameliorating constitution by processed food of rush | |
Williams | A study of the laxative action of wheat bran | |
CN109430838A (en) | A kind of intestinal canal regulating coarse cereals medicinal granules of powder and its processing method | |
KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
Singh et al. | Development of fiber rich powder and effect of supplementation on constipation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20171025 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20181023 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191102 Year of fee payment: 6 |